Parse Biosciences and bit.bio Form Alliance to Build Large-Scale Transcription Factor Map for Predictive Human Biology

-Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, announced an alliance with bit.bio to create a comp...

May 29, 2026 | Friday | News
Abivax SA Demonstrates Durable Seven-Year Remission Data for Obefazimod in Ulcerative Colitis as Phase 3 Readout Nears

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obef...

May 27, 2026 | Wednesday | News
AGC Biologics Selected by Teikoku Seiyaku Co., Ltd. to Advance Microbial Manufacturing for KTP-001 in Lumbar Disc Herniation

AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract...

May 27, 2026 | Wednesday | News
Innovent Biologics, Inc. and HUTCHMED Receive China Approval for TYVYT® Plus ELUNATE® in Advanced Renal Cell Carcinoma

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...

May 26, 2026 | Tuesday | News
Eli Lilly and Company Reports Phase 3 TRIUMPH-1 Trial Shows Up to 30.3% Weight Loss with Retatrutide in Obesity

 In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weig...

May 26, 2026 | Tuesday | News
HDT Bio Receives MCDC Innovation Prototype Award for Advancing HDT-321 CCHF Vaccine into Phase 1 Clinical Trials

HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington,announced that it received the Medical CBRN Defense Consortium (MCDC) Innova...

May 26, 2026 | Tuesday | News
Assembly Biosciences Expands ABI-6250 Development Into Cholestatic Liver Diseases PBC and PSC

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced p...

May 25, 2026 | Monday | News
Boehringer Ingelheim Receives Positive CHMP Recommendation for Nerandomilast in IPF and PPF

European Medicines Agency (EMA) has adopted a positive opinion recommending approval of nerandomilast for the treatment of idiopathic pulmonary fibrosis ...

May 25, 2026 | Monday | News
Myosin Therapeutics Doses First Patient in Phase 1/2 STAR-GBM Trial for Novel Glioblastoma Therapy MT-125

Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, announced that the first patient has been dosed...

May 21, 2026 | Thursday | News
Sanofi’s Phase 2 ElevAATe Data Show Efdoralprin Alfa Superior to Standard Augmentation Therapy in AATD

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD ...

May 20, 2026 | Wednesday | News
Telix Completes Patient Enrolment in IPAX-2 Trial of TLX101-Tx for Newly Diagnosed Glioblastoma

IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities obser...

May 20, 2026 | Wednesday | News
SN BioScience Initiates Global Phase 1b/2 Trial of SNB-101 in Extensive-Stage Small Cell Lung Cancer

SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in i...

May 19, 2026 | Tuesday | News
Racura Oncology Advances CPACS Trial Following Positive Safety Review Committee Recommendation

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced so...

May 19, 2026 | Tuesday | News
LOTTE Biologics Expands Strategic Collaboration with Ottimo Pharma to Advance OTP-01 Toward Commercialization

LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company develo...

May 19, 2026 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close